Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Moderna Stock Surges 6% on News of Potential Multi-Indication Use for Cancer Vaccine

NextEdge Admin

08 Apr 2024

2 min 24 sec

Moderna stock surged by 6% on Tuesday following the release of promising data regarding its cancer vaccine. The data, presented at the American Association for Cancer Research’s annual meeting, indicated potential efficacy beyond the intended target of melanoma.

Moderna revealed that its cancer vaccine exhibited improved overall survival rates in patients with HPV-negative head-and-neck squamous-cell cancer (HNSCC) when combined with Merck’s Keytruda compared to Keytruda alone, as shown in earlier Phase 2/3 studies. The analysis, conducted about nine months post-trial completion on May 4, 2023, involved 28 enrolled individuals, with 22 receiving Moderna’s personalized cancer vaccine, MRNA-4157.

Results indicated a 27% overall response rate (ORR), with 3.4 months of progression-free survival (PFS), and 24.6 months of overall survival (OS). These outcomes were notably superior to Keytruda monotherapy studies, with ORRs of 18% and 15%, PFS of 2.1 months, and OS ranging from 8.4 to 8.8 months.

Jefferies analysts commented favorably on the data, suggesting it could support Moderna’s potential expansion into first-line treatment in combination with PD1 inhibitors. Keytruda, a monoclonal antibody targeting the PD-1 pathway, has already shown efficacy in combination with chemotherapy.

While Moderna is primarily focused on studying the vaccine for melanoma treatment, HNSCC presents a significant unmet medical need, prompting speculation about the company’s future plans. Jefferies anticipates Moderna engaging with the FDA once enrollment in Phase 3 trials progresses significantly, likely in the latter half of the year, potentially paving the way for accelerated approval.